Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review

Nakagawa, Jun; Fujikawa, Keita; Akagi, Midori; Nakaji, Keita; Yasui, Junichi; Hanatani, Yumi; Hara, Toshihide; Mizokami, Akinari; Kawakami, Atsushi

doi:10.1080/24725625.2020.1741116

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant finding in the study of Nakagawa et al [39] was that SAT could be developed during only TNF-a inhibitor treatment. There were no previous reports of SAT associated with other biologic disease-modifying anti--inflammatory drugs (DMARDs) or targeted synthetic DMARDs, such as an IL-6 receptor inhibitor (tocilizumab), cytotoxic T cell antigen 4-Ig (abatacept), IL-17 inhibitors, IL-23 inhibitors or the Janus kinase inhibitors.…”

Section: Tnf-a As An Indicator Of the Condition Of The Thyroid Glandmentioning

confidence: 95%

“…Therefore, inhibiting its activity with antibodies has become an essential treatment method. As the biological treatment (TNF-a inhibitor) has been used more and more, an increased prevalence of subacute thyroiditis (SAT) has been documented [39]. The pandemic of coronavirus disease 19 has shown that the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can also be a potent SAT-triggering factor [6].…”

Section: Tnf-a As An Indicator Of the Condition Of The Thyroid Glandmentioning

confidence: 99%

“…It is assumed that increased production of TNF-a by plasmacytoid dendric cells as a result of biological treatment promotes lymphocyte migration and inflammatory reaction [41]. Another explanation may be related to cytokine imbalance triggered by TNF-a inhibitors [39].…”

Section: Tnf-a As An Indicator Of the Condition Of The Thyroid Glandmentioning

confidence: 99%

See 2 more Smart Citations

Autoimmune disorders and thyroid function in patients with rheumatoid arthritis after biological treatment

Sawicka‐Gutaj

Wietrzyk²,

Zawalna³

et al. 2022

Rheumatology Forum

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) and autoimmune diseases of the thyroid gland (AITD) often occur together. As autoimmune diseases, they share common pathological pathways, reflecting the fact that the treatment of the underlying disease can influence the course of thyroid disorders. The pharmacotherapy of RA is based on the supply of disease-modifying anti-inflammatory drugs with an increasing focus on biologics. This article aims to review the available literature describing the effects of biological treatments on thyroid function. The use of biologi-cal drugs may have the potential benefit of regulating the level of anti-thyroid antibodies. On the other hand, tumour necrosis factor-alpha (TNF-a) inhibitors are not indifferent to thyroid function and may increase the incidence of subacute thyroiditis. The coexistence of AITD and RA prompts consideration of the need for routine thyroid screening in RA patients and for RA screening in patients with thyroid disease who report joint problems.

show abstract

Section: Tnf-a As An Indicator Of the Condition Of The Thyroid Glandmentioning

confidence: 95%

Section: Tnf-a As An Indicator Of the Condition Of The Thyroid Glandmentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune disorders and thyroid function in patients with rheumatoid arthritis after biological treatment

Sawicka‐Gutaj

Wietrzyk²,

Zawalna³

et al. 2022

Rheumatology Forum

View full text Add to dashboard Cite

show abstract

New aspects in the pathogenesis and management of subacute thyroiditis

Stasiak

Lewiński

2021

Rev Endocr Metab Disord

104

106

View full text Add to dashboard Cite

Subacute thyroiditis (SAT) is a thyroid inflammatory disease, whose pathogenesis and determinants of the clinical course were unclear for many decades. The last few years have brought many clinically significant new data on the epidemiology, pathogenesis and management of SAT. Several human leukocyte antigen (HLA) alleles were demonstrated not only to increase the risk of SAT, but also to correlate with SAT clinical course and determine the risk of recurrence. The world-wide epidemic of the coronavirus disease 19 (COVID-19) has provided new observations that the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can be a potent SAT-triggering factor, and that the clinical course of SAT in patients affected by COVID-19 is different from a typical one. Additionally, many new trends in the clinical course are emerging. In the last years, painless course of SAT is more and more often described, constituting a special challenge in patients hospitalized due to COVID-19. Despite an excellent availability of diagnostic methods, several difficulties in SAT differential diagnosis can be currently encountered and the proper diagnosis and treatment is frequently delayed. False positive diagnoses of SAT in patients with malignancies of poor prognosis constitute a life-threatening problem. Taking into account all the new aspects of SAT pathogenesis and of its clinical course, the new – modified – SAT diagnosis criteria have been proposed.

show abstract

Adalimumab

2021

Reactions Weekly

View full text Add to dashboard Cite

Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review

Cited by 4 publications

References 19 publications

Autoimmune disorders and thyroid function in patients with rheumatoid arthritis after biological treatment

Autoimmune disorders and thyroid function in patients with rheumatoid arthritis after biological treatment

New aspects in the pathogenesis and management of subacute thyroiditis

Adalimumab

Contact Info

Product

Resources

About